Literature DB >> 10481967

Serum PSA and age-specific reference ranges in patients with prostatism symptoms.

S Resim1, M Cek, Z G Gürbüz, A Fazlioğlu, T Caşkurlu, A R Uras, G Sevin.   

Abstract

Prostatic specific antigen (PSA), a tumour marker helpful in the diagnosis and follow-up of prostate cancer, may rise due to causes other than prostate cancer (i.e. BPH, acute prostatitis, etc.). Investigations in order to increase the sensitivity and specificity of PSA in prostate carcinoma are being carried out. Serum PSA levels of patients with prostatism with regard to age as well as these levels in the male population at risk but without clinical prostatic disease (those above the age of 40) should be well documented. The aim of this study is to find age-specific values and ranges of PSA in patients with prostatism symptoms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10481967     DOI: 10.1023/a:1007132926635

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

Authors:  T G Armitage; E H Cooper; D W Newling; M R Robinson; I Appleyard
Journal:  Br J Urol       Date:  1988-12

3.  The value of serum prostate specific antigen determinations before and after radical prostatectomy.

Authors:  P H Lange; C J Ercole; D J Lightner; E E Fraley; R Vessella
Journal:  J Urol       Date:  1989-04       Impact factor: 7.450

4.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

Authors:  A W Partin; H B Carter; D W Chan; J I Epstein; J E Oesterling; R C Rock; J P Weber; P C Walsh
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

5.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

6.  PSA density (PSAD). Role in patient evaluation and management.

Authors:  E Seaman; M Whang; C A Olsson; A Katz; W H Cooner; M C Benson
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

7.  Influence of patient age on the serum PSA concentration. An important clinical observation.

Authors:  J E Oesterling; W H Cooner; S J Jacobsen; H A Guess; M M Lieber
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

Review 8.  Analysis of variation in prostate-specific antigen values.

Authors:  M Riehmann; P R Rhodes; T D Cook; G S Grose; R C Bruskewitz
Journal:  Urology       Date:  1993-10       Impact factor: 2.649

9.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors:  M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen.

Authors:  M C Benson; I S Whang; C A Olsson; D J McMahon; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

View more
  2 in total

1.  Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Mohammed Nizar G Battikhi; Hussein Ismail; Qusey Battikhi
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk.

Authors:  M N G Battikhi; I Hussein
Journal:  Int Urol Nephrol       Date:  2006-12-02       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.